EFFECTS OF DEXTRAN-GRAFT-POLYACRYLAMIDE/ZnO NANOPARTICLES ON PROSTATE CANCER CELL LINES IN VITRO.

Q3 Medicine

Experimental oncology Pub Date : 2022-11-01 DOI:10.32471/exp-oncology.2312-8852.vol-44-no-3.18452

P A Virych, T V Zadvorniy, T V Borikun, O O Lykhova, V A Chumachenko, P A Virych, V A Pavlenko, N V Kutsevol, N Yu Lukianova

{"title":"EFFECTS OF DEXTRAN-GRAFT-POLYACRYLAMIDE/ZnO NANOPARTICLES ON PROSTATE CANCER CELL LINES IN VITRO.","authors":"P A Virych, T V Zadvorniy, T V Borikun, O O Lykhova, V A Chumachenko, P A Virych, V A Pavlenko, N V Kutsevol, N Yu Lukianova","doi":"10.32471/exp-oncology.2312-8852.vol-44-no-3.18452","DOIUrl":null,"url":null,"abstract":"Background: The combination of zinc oxide (ZnO) nanoparticles (NPs) with carriers enhances the anticancer effect of nanocomposites.Aim: To explore the mechanisms of cytotoxic action of dextran-graft-polyacrylamide (D-g-PAA/ZnO) NPs against prostate cancers cell lines in vitro.Materials and methods: Dextran-polyacrylamide was used as a matrix for the synthesis of ZnO NPs. Prostate cancer cells LNCaP, DU-145 and PC-3 were treated with D-g-PAA/ZnO NPs. The expression of Bax, Bcl-2, p53 and Ki-67 was studied using immunocytochemical analysis. Cytomorphological changes in cells were detected after their incubation with nanocomposites for 24 h.Results: The treatment with D-g-PAA/ZnO NPs caused the increase in the Bax and p53 and the decrease in Ki-67 and Bcl-2 expression. Morphological changes associated with apoptosis were registered: decrease in cell size, appearance of cytoplasmic vacuolation, condensation of chromatin, blebbing.Conclusions: Treatment with D-g-PAA/ZnO nanocomposite led to the initiation of apoptotic cell death in prostate cancer cells in vitro.","PeriodicalId":12287,"journal":{"name":"Experimental oncology","volume":"44 3","pages":"217-221"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Background: The combination of zinc oxide (ZnO) nanoparticles (NPs) with carriers enhances the anticancer effect of nanocomposites.

Aim: To explore the mechanisms of cytotoxic action of dextran-graft-polyacrylamide (D-g-PAA/ZnO) NPs against prostate cancers cell lines in vitro.

Materials and methods: Dextran-polyacrylamide was used as a matrix for the synthesis of ZnO NPs. Prostate cancer cells LNCaP, DU-145 and PC-3 were treated with D-g-PAA/ZnO NPs. The expression of Bax, Bcl-2, p53 and Ki-67 was studied using immunocytochemical analysis. Cytomorphological changes in cells were detected after their incubation with nanocomposites for 24 h.

Results: The treatment with D-g-PAA/ZnO NPs caused the increase in the Bax and p53 and the decrease in Ki-67 and Bcl-2 expression. Morphological changes associated with apoptosis were registered: decrease in cell size, appearance of cytoplasmic vacuolation, condensation of chromatin, blebbing.

Conclusions: Treatment with D-g-PAA/ZnO nanocomposite led to the initiation of apoptotic cell death in prostate cancer cells in vitro.

查看原文本刊更多论文

葡聚糖-移植物-聚丙烯酰胺/氧化锌纳米颗粒对前列腺癌细胞的体外作用。

背景:氧化锌纳米粒子与载体的结合增强了纳米复合材料的抗癌作用。目的:探讨右旋糖酐-移植物-聚丙烯酰胺(D-g-PAA/ZnO) NPs体外对前列腺癌细胞的细胞毒作用机制。材料与方法:以右旋糖酐-聚丙烯酰胺为基体，合成ZnO纳米粒子。用D-g-PAA/ZnO NPs处理前列腺癌细胞LNCaP、DU-145和PC-3。免疫细胞化学法检测Bax、Bcl-2、p53、Ki-67的表达。结果:D-g-PAA/ZnO NPs处理后，细胞Bax和p53表达升高，Ki-67和Bcl-2表达降低。与细胞凋亡相关的形态学改变:细胞大小减小，细胞质空泡化，染色质凝结，起泡。结论:D-g-PAA/ZnO纳米复合材料在体外诱导前列腺癌细胞凋亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Experimental oncology Medicine-Oncology

CiteScore

1.40

自引率

0.00%

发文量

期刊介绍： The Experimental Oncology is an English-language journal that publishes review articles, original contributions, short communications, case reports and technical advances presenting new data in the field of experimental and fundamental oncology. Manuscripts should be written in English, contain original work, which has not been published or submitted for publication elsewhere. It also implies the transfer of the Copyright from the author to “Experimental Oncology”. No part of journal publications may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the publisher.